Centogene N.V. Total Liabilities
Centogene N.V. total liabilities. Based on the latest financial reports, Centogene N.V. (CNTGF) has total liabilities worth $102.44 Million USD as of December 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Centogene N.V. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Centogene N.V. (2020–2023)
Total liabilities of Centogene N.V. from 2020 to 2023. This chart illustrates how Centogene N.V.'s total liabilities have evolved over time, based on quarterly financial data. Explore CNTGF long-term investment intensity to see how much of total assets are deployed in long-term investments.
Centogene N.V. Competitors by Total Liabilities
The table below lists competitors of Centogene N.V. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Biotech Growth Trust PLC
LSE:BIOG
|
UK | GBX32.10 Million |
|
Anagenics Ltd
AU:AN1
|
Australia | AU$520.80K |
|
ReTo Eco-Solutions Inc
NASDAQ:RETO
|
USA | $7.10 Million |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
Indonesia | Rp22.81 Billion |
|
Thunderstruck Resources Ltd
V:AWE
|
Canada | CA$747.18K |
|
Komarkcorp Bhd
KLSE:7017
|
Malaysia | RM20.93 Million |
|
STRATHMORE PLUS URANIUM
F:TO3
|
Germany | €989.60K |
|
Silver Grail Resources Ltd
V:SVG
|
Canada | CA$429.74K |
Liability Composition Analysis (2020–2023)
This chart breaks down Centogene N.V.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Centogene N.V. (CNTGF) total assets.
Liquidity & Leverage Metrics
Centogene N.V. Total Liabilities Ratios Explained
Centogene N.V. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Centogene N.V.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Centogene N.V. (2020–2023)
The table below shows the annual total liabilities of Centogene N.V. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $102.44 Million | +19.95% |
| 2022-12-31 | $85.40 Million | +33.69% |
| 2021-12-31 | $63.88 Million | -24.84% |
| 2020-12-31 | $84.99 Million | -- |
About Centogene N.V.
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA … Read more